Involving Iga, Igd, Ige, Or Igm Patents (Class 436/513)
-
Patent number: 7608414Abstract: Disclosed are methods for diagnosing and prognosing Inflammatory Bowel disease or Crohn's disease (CD) by measuring levels of antibodies to glycans in a biological sample.Type: GrantFiled: February 8, 2006Date of Patent: October 27, 2009Assignee: Glycominds, LtdInventors: Nir Dotan, Avinoam Dukler, Rom T. Altstock
-
Patent number: 7604957Abstract: A method for food sensitivity panel testing (for sensitivities other than gluten sensitivity) by detecting IgA antibodies in serum is disclosed. A method for testing stool samples for the presence of particular antibodies, which is more sensitive and less invasive than prior art testing methods, is also disclosed for diagnosing immunologic food sensitivities. These methods of diagnosis may be used alone or in combination to further enhance the accuracy of diagnosis.Type: GrantFiled: September 7, 2007Date of Patent: October 20, 2009Inventor: Kenneth D. Fine
-
Patent number: 7601506Abstract: The invention provides a simple method for diagnosing a non-symptomatic or symptomatic human or animal with transmissible spongiform encephalopathy.Type: GrantFiled: July 28, 2006Date of Patent: October 13, 2009Assignee: IDEXX Laboratories, Inc.Inventors: Roy Jackman, Linda Ann Terry, Sally Jane Everest
-
Publication number: 20090253154Abstract: A method for determining the presence of delayed food allergy and intolerance against antigens extracted from modified foods. The method includes determining a level of antibodies against a modified dietary food antigen in blood and mucosal samples from the patient and comparing the level with normal levels of the antibodies. Dietary antigens that were tested include milk and modified milk products; eggs and modified egg products; meat and modified meat products; fish, mollusks, and crustaceans and their modified products; oils, fats and their modified products; grains and modified grain products; pulses, seeds kernels, nuts and their modified products; vegetables and modified vegetable products; fruits and modified fruit products; sugar, modified sugar products, modified chocolate products and confectionery; and spices and their modified forms.Type: ApplicationFiled: April 2, 2008Publication date: October 8, 2009Applicant: Immunosciences Lab., Inc.Inventor: Aristo Vojdani
-
Patent number: 7598028Abstract: The present invention relates to compositions and methods for the detecting, treating, and empirically investigating cellular proliferation disorders and cellular motility disorders. In particular, the present invention provides compositions and methods for using CXCL chemokines (e.g., CXCL1, CXCL5, CXCL6, CXCL12), CXCL receptors (e.g., CXCR1, CXCR2, CXCR4, CXCR7), and/or pathway related compounds (e.g., NF-kappaB, ERK ½, ELK-1) in the diagnosis, treatment, and empirical investigation of prostate disorders (e.g., prostate cancer, benign prostatic hypertrophy, prostatitis).Type: GrantFiled: November 28, 2007Date of Patent: October 6, 2009Assignee: The Regents of the University of MichiganInventor: Jill A. Macoska
-
Patent number: 7592150Abstract: Disclosed are methods for diagnosing Crohn's disease (CD) or anti-phospholipid syndrome by measuring levels of antibodies to glycans in a biological sample.Type: GrantFiled: December 3, 2003Date of Patent: September 22, 2009Assignee: Glycominds, LtdInventors: Nir Dotan, Avinoam Dukler
-
Patent number: 7582443Abstract: The invention is a procedure for measuring the binding of an entity (ligand) to a surface by using a hapten-conjugated version of the ligand (hapten-ligand). An excess of the hapten-ligand is presented to the binding surface and excess (unbound) hapten-ligand is washed off. Bound hapten-ligand is then solubilized (removed) and applied to a membrane support or separated by electrophoresis and applied to a membrane support. Known amounts of hapten-ligand are similarly applied to the membrane, to provide for hapten-ligand standards. The membrane-bound hapten-ligand is detected by application of an enzyme-conjugated antibody to the hapten; or by application of an antibody to the hapten followed by application of an enzyme-conjugated antibody to the anti-hapten antibody. The resultant membrane-associated enzyme is detected and quantitated by the application of a color or light-producing substrate which reacts with the enzyme.Type: GrantFiled: December 5, 2001Date of Patent: September 1, 2009Inventor: Philip Gerard Cavanaugh
-
Patent number: 7575877Abstract: The present invention relates to a method of diagnosing tuberculosis in a subject, said method comprising steps of: detecting anti-Mycobacterium tuberculosis (M.tb.) isocitrate dehydrogenase (ICDs) antibody in the subject, and diagnosing tuberculosis in the subject.Type: GrantFiled: July 20, 2005Date of Patent: August 18, 2009Assignee: Centre for DNA Fingerprinting and Diagnostics, Department of Biotechnology, Ministry of Science & Technology, Government of India. Nacharam.Inventors: Seyed Ehtesham Hasnain, Sharmistha Banerjee, Ashok Nandyala, Raviprasad Podili, Vishaw M Katoch, Kolluri Janaki Rama Murthy
-
Patent number: 7569390Abstract: A general immunoglobulin-target assay system is provided, in which a positive outcome (the generation of a signal) depends only on the intracellular interaction of immunoglobulin with target. This can be accomplished for many immunoglobulins expressed in yeast and/or in mammalian cells and allows the selection of immunoglobulins which are capable of functioning in an intracellular environment.Type: GrantFiled: March 10, 2000Date of Patent: August 4, 2009Assignees: Medical Research Council, Scuola Internazionale Superiore Di Studi AvanzatiInventors: Tse Wai-Choi Eric, Terenos Rabbits, Antonio Cattaneo, Michela Visintin
-
Patent number: 7547554Abstract: The invention relates to a method and a device for detecting very small quantities of particles. The inventive method is based on a detection of antigen-antibody reaction products and provides a very high detection sensitivity all the way to the femtomolar or attomolar range.Type: GrantFiled: September 9, 2004Date of Patent: June 16, 2009Inventor: Constantin Odefey
-
Publication number: 20090092966Abstract: Metal colloidal aggregates substrates useful for metal enhanced fluorescence applications, are disclosed. Method of making and using these colloidal aggregates for enhancing the fluorescent signal in biological assays are also described.Type: ApplicationFiled: May 30, 2007Publication date: April 9, 2009Applicant: LI-COR, Inc.Inventors: Jon P. Anderson, Teresa M. Urlacher
-
Patent number: 7514226Abstract: The invention provides methods for identifying antibody preparations that can form a pair of antibodies that optimally detect a target antigen, for example, in a sandwich immunoassay. These methods provide high affinity and epitope-specific antibodies.Type: GrantFiled: July 26, 2005Date of Patent: April 7, 2009Assignee: Kimberly-Clark Worldwide, Inc.Inventor: RameshBabu Boga
-
Publication number: 20090075395Abstract: The present invention relates to a method for diagnosing a subject's Alzheimer's disease state. The method involves providing a database containing information relating to protein expression levels associated and not associated with Alzheimer's disease. The database includes information relating to at least a majority of the following proteins: albumin, alpha-1-antitrypsin, apolipoprotin E, apolipoprotein J, complement component 3, contactin, fibrin beta, Ig heavy chain, Ig light chain, neuronal pentraxin receptor, plasminogen, proSAAS, retinol-binding protein, transthyretin, and vitamin D binding protein. Information relating to proteins found in one or more cerebrospinal fluid samples from a subject is also provided and a database is used to analyze the information from the subject to diagnose the subject's Alzheimer's disease state. Also disclosed is a computer readable medium and a system, both useful in carrying out the present invention.Type: ApplicationFiled: April 10, 2006Publication date: March 19, 2009Applicant: CORNELL RESEARCH FOUNDATION, INC,Inventors: Kelvin H. Lee, Norman R. Relkin, Erin Finehout
-
Patent number: 7485430Abstract: The present invention concerns compositions and methods for evaluating fertility in humans and animals. The invention may also be used to identify reproductive cancers such as testicular cancer. In various embodiments of the invention, an Sptrx-3 enzyme is used as a fertility marker. Sptrx-3 may be detected in accordance with the invention in vitro or in vivo.Type: GrantFiled: April 15, 2005Date of Patent: February 3, 2009Assignee: The Curators of the University of MissouriInventors: Peter Sutovsky, Antonio Miranda-Vizuete
-
Publication number: 20090028843Abstract: The invention relates to a method for determining susceptibility to an IgA-related disorder in an animal, the method comprising: a) identifying the or each IgA allelic variant present in a sample from the animal; and b) thereby determining whether the animal is susceptible to an IgA-related disorder.Type: ApplicationFiled: November 30, 2005Publication date: January 29, 2009Inventors: Chris Jones, Neale Fretwell, Michael Day, Iain Peters
-
Patent number: 7473551Abstract: The present invention relates generally to methods and compositions for analyzing test samples containing target analytes including proteins and nucleic acids. The invention uses a surface acoustic wave sensor in combination with a hydrogel to obtain an ultra sensitive non-fluorescent detection system.Type: GrantFiled: May 20, 2005Date of Patent: January 6, 2009Assignee: Atonomics A/SInventor: Peter Warthoe
-
Patent number: 7456264Abstract: Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: May 21, 2004Date of Patent: November 25, 2008Assignee: Medarex, Inc.Inventors: Tibor Keler, Israel Lowy, Laura A. Vitale, Diann Blanset, Mohan Srinivasan
-
Patent number: 7452731Abstract: A method for determining the risk of an individual of suffering from inflammation, opportunistic infection or disruption of immunoglobulin metabolism, comprising (a) determining the level of fragmentation or modification of Fc function of immunoglobulins in a sample taken from the individual and (b) determining thereby the risk of inflammation, impaired immune response or opportunistic infection. The invention also provides the use of a trypsin inhibitor in the manufacture of a medicament for use in the treatment or prevention of a disorder associated with elevated trypsin activity which is correlated with IgG fragmentation or modification.Type: GrantFiled: February 15, 2002Date of Patent: November 18, 2008Inventor: Ivan Mikhailovich Petyaev
-
Publication number: 20080280828Abstract: The present invention relates generally to methods and materials for treating conditions associated with IgE activation in humans and animals, and to agents capable of modulating the activation. The agents of the invention comprise or are related to IGBPMA polypeptides from ticks.Type: ApplicationFiled: October 26, 2006Publication date: November 13, 2008Inventors: Hui Wang, Patricia Anne Nuttall
-
Publication number: 20080274463Abstract: Disclosed embodiments concern quantifying a biomolecule conjugated to a nanoparticle. Quantifying typically comprises determining the number of biomolecules per nanoparticle. Any suitable biomolecule can be used, including but not limited to, amino acids, peptides, proteins, haptens, nucleic acids, oligonucleotides, DNA, RNA, and combinations thereof. A single type of biomolecule may be conjugated to the nanoparticle, more than one biomolecule of a particular class may be conjugated to the nanoparticle, or two or more classes of biomolecules may be conjugated to the nanoparticle. Certain disclosed embodiments comprise enzymatically or chemically digesting a biomolecule conjugated to the nanoparticle, or displacing a biomolecule using ligand-exchange chemistry.Type: ApplicationFiled: May 4, 2007Publication date: November 6, 2008Inventors: Xiao-Bo Chen, Christopher Bieniarz, Michael Farrell
-
Patent number: 7413892Abstract: Acoustic wave devices coated with a biolayer are described for the detection target bio-molecules. The acoustic wave device is connected in an oscillator circuit, and the frequency shift ?f resulting from a biomolecular event is recorded. Further described are the use of Rayleigh wave surface acoustic wave devices for vapor phase detection as well as quartz crystal microbalance devices for liquid phase measurements. A biofilm on the surface of the acoustic wave device comprises of a layer of antibodies raised against a specific target molecule or antigen. Signatures for detection events are presented in the form of frequency shifts ?f(t).Type: GrantFiled: June 7, 2004Date of Patent: August 19, 2008Assignee: Georgia Tech Research CorporationInventor: William D. Hunt
-
Patent number: 7407764Abstract: This invention provides the first blood test which characterizes asthma severity. More specifically, the present invention provides methods of determining the severity of acute asthma in a patient by determining the levels of C5a or C5a-desArg in the patient's blood, plasma or serum.Type: GrantFiled: October 17, 2005Date of Patent: August 5, 2008Assignee: The Research Foundation of State University of New YorkInventors: Rauno Joks, Hazel P. Drew, Myrelle B. Castro, Nandita Mathur Khaneja
-
Publication number: 20080176254Abstract: The present invention provides compositions and methods for affinity separation of targets from mixtures. In particular, disclosed are avian IgY antibodies coupled to solid supports and their methods of use.Type: ApplicationFiled: October 18, 2007Publication date: July 24, 2008Inventors: Xiangming Fang, Lei Huang, Ping Lin, Jerald S. Feitelson, Wei-Wei Zhang
-
Patent number: 7399470Abstract: A sandwich immunoassay kit for detecting ciguatoxins based on a combination of two anti-ciguatoxin CTX3C monoclonal antibodies produced by hybridomas, 3D11 (deposited at IPOD, AIST under accession number FMRM PB-8293) and 10C9 (FMRM PB-8292). In particular, one of the antibodies is labeled and each of them binds specifically to a different site of ciguatoxin CTX3C.Type: GrantFiled: March 10, 2003Date of Patent: July 15, 2008Assignee: Japan Science and Technology AgencyInventors: Masahiro Hirama, Hiroki Oguri, Ikuo Fujii, Takeshi Tsuburaya
-
Publication number: 20080166719Abstract: The present invention provides methods, systems, and code for accurately classifying whether a sample from an individual is associated with irritable bowel syndrome (IBS). In particular, the present invention is useful for classifying a sample from an individual as an IBS sample using a statistical algorithm and/or empirical data. The present invention is also useful for ruling out one or more diseases or disorders that present with IBS-like symptoms and ruling in IBS using a combination of statistical algorithms and/or empirical data. Thus, the present invention provides an accurate diagnostic prediction of IBS and prognostic information useful for guiding treatment decisions.Type: ApplicationFiled: August 20, 2007Publication date: July 10, 2008Applicant: Prometheus Laboratories Inc.Inventor: Augusto Lois
-
Patent number: 7393697Abstract: Diagnostic devices and methods are provided. The diagnostic devices preferably comprise a test strip with a test area. The sample to be analyzed contacts the test area, which comprises a specific binding partner for the analyte of interest. Analyte, if present in the sample, binds to the immobilized binding partner in the test area and is subsequently contacted with a conjugate. The conjugate specifically binds the analyte and provides a visual indication of the presence of the analyte. The devices may be used for the diagnosis of particular diseases or disorders in a patient, such as HIV or hepatitis. They may also be used to determine if an individual is pregnant.Type: GrantFiled: June 6, 2003Date of Patent: July 1, 2008Assignee: Advantage Diagnostics CorporationInventor: David Charlton
-
Publication number: 20080153116Abstract: A diagnostic test and method is provided comprising mixing blood or another biological fluid sample with a test compound and spotting the blood on filter paper for subsequent analysis of the effect of the test compound on the blood. The biological fluid can be a cerebrospinal fluid, a peritoneal fluid, a cyst fluid, an amniotic fluid, a lavage fluid, a saliva, a cell extract or a tissue extract. The compound is chosen among an amino acid, a peptide, a protein, a carbohydrate, an oligosaccharide, a polysaccharide, a glycoprotein, a lipid, a lipoprotein, a glycosaminoglycan, a hormone, a steroid, a vitamin, a low molecular weight synthetic or natural compound which influences the blood to cause an alteration of its composition, e.g., a toxin, allergen, autoantigen, bacterial protein or polysaccharide, viral protein, fungal protein or polysaccharide, parasitic protein or polysaccharide, bacterial lipopolysaccharide or any other compound relevant to diseases.Type: ApplicationFiled: November 30, 2007Publication date: June 26, 2008Applicant: Statens Serum InstituteInventors: Gunnar HOUEN, David Hougaard, Kristin Skogstrand, Charlotte Svaerke Jorgensen
-
Publication number: 20080131439Abstract: The present invention provides methods, systems, and code for accurately classifying whether a sample from an individual is associated with inflammatory bowel disease (IBD) or a clinical subtype thereof. In particular, the present invention is useful for classifying a sample from an individual as an IBD sample using a statistical algorithm and/or empirical data. The present invention is also useful for differentiating between a clinical subtype of IBD such as Crohn's disease (CD) and ulcerative colitis (UC) using a statistical algorithm and/or empirical data. Thus, the present invention provides an accurate diagnostic prediction of IBD or a clinical subtype thereof and prognostic information useful for guiding treatment decisions.Type: ApplicationFiled: November 30, 2006Publication date: June 5, 2008Applicant: Prometheus Laboratories Inc.Inventors: Augusto Lois, Bruce Neri
-
Patent number: 7361480Abstract: The invention is directed to a method of detecting gluten-induced diseases such as e.g. celiac disease and dermatitis herpetiformis. Said diseases are indicated by the presence of autoantibodies against tissue transglutaminase tTG in the blood The test is carried out on a whole blood sample using tTG liberated from the red blood cells of the blood sample as an autoantigen. The liberated autoantigens react with the autoantibodies in the sample and form antigen-antibody complexes, which are detected. The presence of such complexes indicates the disease. The invention is also directed to the use of the autoantigen in a test and to a test-kit.Type: GrantFiled: April 24, 2002Date of Patent: April 22, 2008Inventors: Markku Mäki, Ilma Korponay-Szabo
-
Patent number: 7361479Abstract: The present invention provides a method of determining the presence or amount of newly synthesized antibody in a sample in response to an immunogen by detecting the released antibodies or parts thereof in a sample containing lymphocytes which have been disrupted whereby to release the synthesized antibodies or parts thereof associated with said lymphocytes whereby to determine the presence or amount of newly synthesized antibody in said sample, methods of diagnosis using said method and kits for performing the method. The method may also be modified to allow detection of non-specific infection indicators.Type: GrantFiled: June 14, 2000Date of Patent: April 22, 2008Assignee: PlasmAcute ASInventor: Lars Reinhardt Haaheim
-
Patent number: 7358058Abstract: Methods for diagnosis, early diagnosis, differential diagnosis, assessment of the severity and therapy-accompanying monitoring and prognosis of chronically inflammatory intestinal diseases (Crohn's disease, Colitis ulcerosa), in which the presence and/or the amount of one or more antibodies which bind to ribosomal proteins, in particular P0 and L5, are determined in the serum, plasma, tissue samples and/or stool of a patient who is suffering from a chronically inflammatory intestinal disease or in whom such a disease is suspected. The blocking or removal of such antibodies and/or the influencing of antigen-presenting cells or specifically reactive T-cells which react to ribosomal proteins, such as P0 and L5, by suitable agents can be therapeutically utilized.Type: GrantFiled: September 3, 2002Date of Patent: April 15, 2008Assignee: B.R.A.H.M.S AktiengesellschaftInventors: Andreas Bergmann, Marita Willnich, Detlef Schuppan
-
Patent number: 7341839Abstract: Diagnostic methods for identifying a test subject who has or is at risk of developing age-related macular degeneration (AMD) or an analogous disease associated with oxidation of DHA-containing lipids are provided. In one aspect, the methods comprise: assaying for the presence of elevated levels of 2-(?-carboxyethyl) pyrrole (CEP) adducts in a bodily fluid which has been obtained from the test subject. In a preferred embodiment, such methods comprise providing an antibody that is immunospecific for CEP, contacting a bodily fluid from the subject with the anti-CEP antibody, and assaying for the formation of a complex between the antibody and an antigen in the sample. In another aspect, the methods comprise assaying for the presence of elevated levels of an antibody that binds to or is immunospecific for a CEP adduct in the bodily fluid of the test subject. The present invention also relates to CEP protein and peptide adducts, an antibody reactive with a CEP adduct and a diagnostic kit comprising such antibody.Type: GrantFiled: September 20, 2006Date of Patent: March 11, 2008Assignees: The Cleveland Clinic Foundation, Case Western Reserve UniversityInventors: Joe G. Hollyfield, Robert G. Salomon, John W. Crabb, Xiaorong Gu
-
Patent number: 7329536Abstract: An apparatus comprising one or more piezoelectric mass sensors for use in diagnostic and analytic processes, in particular for immunochemical detection of diagnostically relevant analytes in real time, is described. Each piezoelectric mass sensor comprises a piezoelectric crystal with a receptor surface which has immobilized thereon a lawn of recombinant antibodies comprising single VH chain or single-chain Fv (scFv) polypeptides specific for a particular antigen. Binding of antigen to the recombinant antibodies results in a change in mass on the receptor surface which is detected as a change in resonant frequency. In a preferred embodiment, the receptor layer is a precious metal such as gold which facilitates self-assembly of the recombinant antibodies into a lawn on the receptor surface via a cysteine residue at the carboxy terminus of the attachment polypeptide.Type: GrantFiled: June 4, 2004Date of Patent: February 12, 2008Assignees: Oakland University, Vanderbilt UniversityInventors: Xiangqun Zeng, Gabrielle Stryker, Raymond L. Mernaugh
-
Patent number: 7306919Abstract: A method for the isolation and purification of a cancer recognition (CARE) antigen about 66,000 Dalton molecular weight with a pH between 4.5 and 6.5, and detection of antibodies to this CARE antigen (CARE antibody). The CARE antigen and CARE antibody are cancer markers for a broad range of cancers and can be detected in fluids or tissues of cancer patients with simple ELISA assays. The combined use of these assays for both the CARE antigen and the CARE antibody provide improved sensitivity and selectivity for cancer detection compared to assaying for the antigen or antibody alone. The CARE antigen and antibodies to this antigen have therapeutic usefulness.Type: GrantFiled: October 31, 2001Date of Patent: December 11, 2007Inventor: Jerry T. Thornthwaite
-
Patent number: 7285424Abstract: A membrane-based assay device for detecting the presence or quantity of an analyte residing in a test sample is provided. The device utilizes a self-calibrated magnetic binding assay format (e.g., sandwich, competitive, etc.) that includes detection probes capable of generating a detection signal (e.g., fluorescent non-magnetic particles) and calibration probes capable of generating a calibration signal (e.g., fluorescent magnetic particles). The amount of the analyte within the test sample is proportional (e.g., directly or inversely) to the intensity of the detection signal calibrated by the intensity of the calibration signal. It has been discovered that the fluidics-based device of the present invention provides an accurate, inexpensive, and readily controllable method of determining the presence of an analyte in a test sample.Type: GrantFiled: August 27, 2002Date of Patent: October 23, 2007Assignee: Kimberly-Clark Worldwide, Inc.Inventors: Xuedong Song, Rosann Kaylor
-
Patent number: 7258994Abstract: A method for diagnosing the likelihood and severity of cardiovascular disease in a patient is disclosed. The method determines the levels of antibodies against autoantigens, including myosin, oxidized LDL, ?-2-glycoprotein, heat shock protein-60, platelet glycoprotein, and immune complexes. It then compares the results to normal levels to determine the likelihood and severity of cardiovascular disease.Type: GrantFiled: January 9, 2006Date of Patent: August 21, 2007Assignee: Immunosciences Lab., Inc.Inventor: Aristo Vojdani
-
Patent number: 7244580Abstract: The present invention relates to identification of polypeptides useful for generating antibodies specific for non-human IgE, particularly equine IgE. The invention, therefore, also relates to antibodies that specifically bind to IgE and methods to detect IgE using the antibodies. The invention also provides a kit for detection of IgE.Type: GrantFiled: November 8, 2001Date of Patent: July 17, 2007Assignee: The Regents of the University of CaliforniaInventors: Laurel J. Gershwin, Howard David Pettigrew, Warren V. Kalina
-
Patent number: 7223534Abstract: A biosensor includes a substrate with a layer of receptive material disposed thereon. The receptive material is specific for an analyte of interest. A pattern of active and deactivated areas of the receptive material are defined in the receptive material layer by a masking process.Type: GrantFiled: May 3, 2002Date of Patent: May 29, 2007Assignee: Kimberly-Clark Worldwide, Inc.Inventors: Rosann Kaylor, David Cohen, Curtis Sayre
-
Patent number: 7214493Abstract: A humanized antibody that binds to human 4-1BB and that allows binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating cancer in a subject comprising administering a therapeutically effective amount of the antibody to said subject.Type: GrantFiled: March 7, 2005Date of Patent: May 8, 2007Assignee: Bristol-Myers Squibb CompanyInventors: Maria Jure Kunkel, Subinay Ganguly, Ralph Abraham, Diane L. Hollenbaugh, Jill Rillema, Barbara Thorne, Walter W. Shuford, Robert S. Mittler
-
Patent number: 7205382Abstract: Peptides having the following amino acid sequence as well as peptides or proteins which contain this amino acid sequence: R1-X01-X02-X03-X04-X05-X06-X07-X08-X09-X10-X11-X12-X13-R2. These peptides have a high affinity for immunoglobulins. Applications of the peptides according to the invention are also described.Type: GrantFiled: November 8, 2001Date of Patent: April 17, 2007Assignee: Fresenius Medical Care Affina GmbHInventors: Wolfgang Rönspeck, Ralf Egner, Dirk Winkler, Rudolf Kunze
-
Patent number: 7195881Abstract: The invention relates to a method for detecting and supervising neurodegenerative diseases, which consists in detecting the presence of antibodies of the A-isotype and/or M-isotype which are directed against the antigens which are associated with these diseases. The invention also relates to a kit for the implementation of this method.Type: GrantFiled: March 15, 2002Date of Patent: March 27, 2007Assignee: GEMACInventor: Michel Geffard
-
Patent number: 7172874Abstract: Diagnostic methods for identifying a test subject who has or is at risk of developing age-related macular degeneration (AMD) or an analogous disease associated with oxidation of DHA-containing lipids are provided. In one aspect, the methods comprise: assaying for the presence of elevated levels of 2-(?-carboxyethyl) pyrrole (CEP) adducts in a bodily fluid which has been obtained from the test subject. In a preferred embodiment, such methods comprise providing an antibody that is immunospecific for CEP, contacting a bodily fluid from the subject with the anti-CEP antibody, and assaying for the formation of a complex between the antibody and an antigen in the sample. In another aspect, the methods comprise assaying for the presence of elevated levels of an antibody that binds to or is immunospecific for a CEP adduct in the bodily fluid of the test subject. The present invention also relates to CEP protein and peptide adducts, an antibody reactive with a CEP adduct and a diagnostic kit comprising such antibody.Type: GrantFiled: April 30, 2002Date of Patent: February 6, 2007Assignees: The Cleveland Clinic Foundation, Case Western Reserve UniversityInventors: Joe G. Hollyfield, Robert G. Salomon, John W. Crabb, Xiaorong Gu
-
Patent number: 7169550Abstract: A biosensor includes a substrate with a receptive material layer of radiation-absorbing member (RAM)-tagged biomolecules disposed thereon. The receptive material is specific for an analyte of interest. A pattern of active and deactivated areas of the receptive material are defined in the receptive material layer by a masking process wherein areas are exposed through a mask with a light source to induce deactivation.Type: GrantFiled: September 26, 2002Date of Patent: January 30, 2007Assignee: Kimberly-Clark Worldwide, Inc.Inventors: Curtis Sayre, Rosann Kaylor, David Cohen
-
Patent number: 7144742Abstract: This invention provides solid phase specific binding lateral flow assay methods, devices and kits for quantitating high and low molecular weight analytes. The methods and devices of the invention employ labelled reagents which are either analyte analogs or complementary specific binding pair members for the analyte and a novel arrangement of capture zones comprising immobilized specific binding substances for either the analyte or the labelled reagent to effect bound from unbound labelled reagent as a function of analyte concentration. The capture zones are disposed on a non-bibulous matrix defining a flow path from a sample receiving zone to the capture zone. The devices of this invention also include multilane flow paths and multiple capture zones to quantitate analyte.Type: GrantFiled: December 17, 2004Date of Patent: December 5, 2006Assignee: Quidel CorporationInventors: Hans Boehringer, Gerald Rowley, Allan D. Pronovost
-
Patent number: 7138237Abstract: The present invention provides a method of diagnosing Crohn's disease in a subject by determining the presence or absence of IgA anti-OmpC antibodies in the subject, where the presence of the IgA anti-OmpC antibodies indicates that the subject has Crohn's disease.Type: GrantFiled: May 19, 2000Date of Patent: November 21, 2006Assignees: Cedars-Sinai Medical Center, The Regents of the University of CaliforniaInventors: Stephan R. Targan, Jonathan Braun, Christopher L. Sutton
-
Patent number: 7101851Abstract: The invention provides novel compounds which bind to the high affinity receptor for immunoglobulin E (IgE) designated Fc?RI and methods for identifying and preparing such compounds. In particular aspects, the invention provides to the treatment of disorders mediated by IgE utilizing the novel compounds of the invention. The invention also provides composition, such as pharmaceutical compositions, comprising the novel compounds, as well as for their use in research, diagnostic, therapeutic, and prophylactic methods.Type: GrantFiled: September 26, 2001Date of Patent: September 5, 2006Assignee: Genentech, Inc.Inventors: Henry B. Lowman, Gerald R. Nakamura, Mark E. Reynolds, Melissa A. Starovasnik
-
Patent number: 7091049Abstract: An enhanced diffraction based biosensor system and method are provided for detecting an analyte of interest in a test medium. The system incorporates at least one additional detection tag substance with the analyte of interest, the tag emitting a measurable parameter that is different from optical diffraction characteristics of the analyte. The biosensor may be a “fluoroptical” system wherein the detection tag is a fluorescence emitting substance, including fluorescent-labeled diffraction enhancing elements. The enhanced diffraction biosensor system may determine the presence of analytes in biological fluids both qualitatively and quantitatively.Type: GrantFiled: June 26, 2002Date of Patent: August 15, 2006Assignee: Kimberly-Clark Worldwide, Inc.Inventors: Rameshbabu Boga, Chibueze Obinna Chidebelu-Eze, Rosann M. Kaylor, Xuedong Song
-
Patent number: 7090984Abstract: A method for detecting a substance, comprising developing a developing liquid through a test region up to a reference region, and a detection device for use therein, wherein the reference region comprises a metal compound other than an alkali metal salt, and the developing liquid that reaches the reference region contains a label that can be accumulated in the reference region. The label is preferably a colored particle, and is preferably bound to an antibody or an antigen.Type: GrantFiled: October 25, 2001Date of Patent: August 15, 2006Assignee: Morinaga Milk Industry Co., Ltd.Inventors: Koichi Hashimoto, Yoshitsugu Harada, Shigetoshi Okubo
-
Surface plasmon resonance biosensor for measurement of anti-glycolipid antibody levels in neuropathy
Patent number: 7074621Abstract: The present invention provides a method of detecting human antibodies in a sera solution. The invention also provides a method of quantitating anti-glycolipid antibody levels in solutions. The invention provides a method of diagnosing disease states, including neurological diseases, by quantitating a subject's antibody levels.Type: GrantFiled: May 3, 2004Date of Patent: July 11, 2006Assignee: The Trustees of Columbia University in the City of New YorkInventors: Norman Latov, Armin Alaedini -
Patent number: 7074586Abstract: A method for quantitatively assaying one or more target molecules in a sample uses a nucleic acid aptamer that is specific for each target molecule. A quantitative replicative procedure is used to determine a quantity of aptamer specific for each molecule.Type: GrantFiled: June 16, 2000Date of Patent: July 11, 2006Assignee: Source Precision Medicine, Inc.Inventors: John C. Cheronis, David Trollinger